These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 35986599

  • 1. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
    Lin KH, Lai YC, Lin YP, Ho MW, Chen YC, Chung WH.
    Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
    Carvajal SK, Melendres J, Escandón P, Firacative C.
    Microbiol Spectr; 2023 Aug 17; 11(4):e0140323. PubMed ID: 37341584
    [Abstract] [Full Text] [Related]

  • 4. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J.
    J Med Microbiol; 2011 Jul 17; 60(Pt 7):961-967. PubMed ID: 21393452
    [Abstract] [Full Text] [Related]

  • 5. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
    Herkert PF, Hagen F, de Oliveira Salvador GL, Gomes RR, Ferreira MS, Vicente VA, Muro MD, Pinheiro RL, Meis JF, Queiroz-Telles F.
    Eur J Clin Microbiol Infect Dis; 2016 Nov 17; 35(11):1803-1810. PubMed ID: 27477855
    [Abstract] [Full Text] [Related]

  • 6. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM, Almeida-Paes R, Brito-Santos F, Nascimento CR, Fialho MM, Trilles L, Morales BP, da Silva SA, Santos W, Santos LO, Fortes ST, Cardarelli-Leite P, Lázera MDS.
    Med Mycol; 2019 Oct 01; 57(7):864-873. PubMed ID: 30657975
    [Abstract] [Full Text] [Related]

  • 7. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the Cryptococcus neoformans Complex in Jiangxi Province, South Central China.
    Yang C, Bian Z, Blechert O, Deng F, Chen H, Li Y, Yang Y, Chen M, Zhan P.
    Front Cell Infect Microbiol; 2021 Oct 01; 11():723251. PubMed ID: 34790585
    [Abstract] [Full Text] [Related]

  • 8. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS, Nawange SR, Singh SM, Yadu R, Tiwari A, Gumasta R, Kavishwar A.
    Braz J Microbiol; 2015 Oct 01; 46(4):1125-33. PubMed ID: 26691471
    [Abstract] [Full Text] [Related]

  • 9. Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
    Lahiri Mukhopadhyay S, Bahubali VH, Manjunath N, Swaminathan A, Maji S, Palaniappan M, Parthasarathy S, Chandrashekar N.
    Mycoses; 2017 Nov 01; 60(11):749-757. PubMed ID: 28736880
    [Abstract] [Full Text] [Related]

  • 10. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F, Gritsenko V, Lu H, Zhen C, Gao L, Berman J, Jiang YY.
    Microbiol Spectr; 2021 Oct 31; 9(2):e0072321. PubMed ID: 34585947
    [Abstract] [Full Text] [Related]

  • 11. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA, Arthur I, Merritt A, Leung M.
    Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538
    [Abstract] [Full Text] [Related]

  • 12. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
    Moreira IMB, Cortez ACA, de Souza ÉS, Pinheiro SB, de Souza Oliveira JG, Sadahiro A, Cruz KS, Matsuura ABJ, Melhem MSC, Frickmann H, de Souza JVB.
    Med Mycol; 2022 Mar 03; 60(3):. PubMed ID: 35084497
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
    Chong HS, Dagg R, Malik R, Chen S, Carter D.
    J Clin Microbiol; 2010 Nov 03; 48(11):4115-20. PubMed ID: 20844209
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
    Kassi FK, Bellet V, Drakulovski P, Krasteva D, Roger F, Valérie BA, Aboubakar T, Doumbia A, Kouakou GA, Delaporte E, Reynes J, Yavo W, Menan HIE, Bertout S.
    J Med Microbiol; 2018 Jan 03; 67(1):87-96. PubMed ID: 29214970
    [Abstract] [Full Text] [Related]

  • 20. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC, de Paula DA, Dutra V, Nakazato L, Tadano T, Lazera Mdos S, Wanke B, Trilles L, Walderez Szeszs M, Silva D, Hahn RC.
    J Infect Dev Ctries; 2014 Aug 13; 8(8):1037-43. PubMed ID: 25116671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.